Advertisement

Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      ChromosorbR column chromatography was used for separation of RU 486 from its immunologically cross-reacting metabolites prior to quantitative analysis by radioimmunoassay (RIA) or high-performanceliquid chromatography (HPLC). The results of the two assay methods were in good agreement with each other (r=0.99, n=29). The retention time of RU 486 in our HPLC system was 2.5 min.
      Plasma concentrations of RU 486 were measured by HPLC up to 48 h following single oral administration of 100, 400, 600 and 800 mg of RU 486 to female volunteers. The plasma peak concentrations (2.0 – 2.5 μg/ml) were reached within the first hour. After redistribution, the plasma concentrations of RU 486 were not significantly affected by the doses studied but remained in the same range throughout the 48 hours. The plasma half-life between 24 and 48 hours was 27 hours or more.
      We conclude that HPLC is valuable in studies on the metabolism and pharmacokinetics of RU 486, but a less laborious RIA method after ChromosorbR column chromatography is suitable and gives reliable results in large-scale clinical studies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. (Abstract No. 668.)
        • Philibert D.
        • Deraedt R.
        • Teutsch G.
        • Tournemine C.
        • Sakiz E.
        RU 486: a new lead for steroidal anti-hormones.
        in: Sixty-Fourth Annual Meeting of the Endocrine Society, San Francisco, June 16 to 181982
      2. (Abstract No. 1463.)
        • Philibert D.
        • Deraedt R.
        • Teutsch G.
        RU 38486 — A potent antiglucocorticoid in vivo.
        in: VIII International Congress of Pharmacology, Tokyo, July 19 to 241981
        • Moguilewsky M.
        • Philibert D.
        RU 38486: Potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by an impaired activation.
        J. Steroid Biochem. 1984; 20: 271-276
        • Herrmann W.
        • Wyss R.
        • Riondel A.
        • Philibert D.
        • Teutsch G.
        • Sakiz E.
        • Baulieu E.E.
        The effects of an antiprogesterone steroid on women: interruption of the menstrual cycle and of early pregnancy.
        C. R. Acad. Sc. Paris. 1982; 294: 933-938
        • Gravanis A.
        • Schaison G.
        • George M.
        • de Brux J.
        • Satyaswaroop G.
        • Baulieu E.E.
        • Robel P.
        Endometrial and pituitary reponses to the steroidal antiprogestin RU 486 in postmenopausal women.
        J. Clin. Endocrinol. Metab. 1985; 60: 156-163
        • Salmon J.
        • Mouren M.
        Radioimmunoassay of RU 486.
        in: Segal S.J. Baulieu E.E. The Antiprogesterone Steroid RU 486 and Human Fertility Control. Plenum Press, Heidelberg1985: 99-101
        • Philibert D.
        Segal S.J. Baulieu E.E. Proceedings on RU 486. Bellagio, New York1984
        • Shoupe D.
        • Mishell D.
        • Lacarra M.
        • Gutierrez E.
        • Lähteenmäki P.
        • Spitz I.
        Endocrinologic effects of the antiprogesterone RU 486 in the luteal phase of normal women.
        in: Segal S.J. Baulieu E.E. The Antiprogesterone Steroid RU 486 and Human Fertility Control. Plenum Press, Italy1985: 285-293
        • Schreiber J.
        • Hsueh A.
        • Baulieu E.E.
        Binding of the antiprogestin RU-486 to rat ovary steroid receptors.
        Contraception. 1983; 28: 77-85
        • Chrousos G.
        • Cutler G.
        • Simons S.
        • Pons M.
        • Moriarty R.
        • Loriaux D.
        Development of antiglucocorticoids with potential clinical usefulness.
        in: Progress in Research and Clinical Applications of Corticosteroids. Heyden and Son Inc., New York1982: 152-176
        • Deraedt R.
        • Bonnat C.
        • Busigny M.
        • Chatelet P.
        • Cousty C.
        • Mouren M.
        • Philibert D.
        • Pottier J.
        • Salmon J.
        Pharmacokinetics of RU 486.
        in: Segal S.J. Baulieu E.E. The Antiprogesterone Steroid RU 486 and Human Fertility Control. Plenum Press, Philadelphia1985: 103-122
        • Bertagna X.
        • Bertagna C.
        • Luton J-P.
        • Husson J-M
        • Girard F.
        The new steroid analog RU 486 inhibits glucocorticoid action in man.
        J. Clin. Endocrinol. Metab. 1984; 59: 25-28
        • Gaillard R.
        • Poffet D.
        • Riondel A.
        • Saurat J-H.
        RU 486 inhibits peripheral effects of glucocorticoids in humans.
        J. Clin. Endocrinol. Metab. 1985; 61: 1009-1011